<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04299906</url>
  </required_header>
  <id_info>
    <org_study_id>FCRE-191127</org_study_id>
    <nct_id>NCT04299906</nct_id>
  </id_info>
  <brief_title>SOLARIS Peripheral PMCF Trial</brief_title>
  <official_title>Physician-Initiated PMCF Trial Investigating the Solaris Vascular Stent Graft for the Treatment of Iliac Lesions - SOLARIS Peripheral PMCF Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Giovanni Torsello</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FCRE (Foundation for Cardiovascular Research and Education)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>FCRE (Foundation for Cardiovascular Research and Education)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this clinical investigation is to evaluate, in a controlled setting, the
      long-term (up to 12 months) safety and efficacy of the Solaris Vascular Stent Graft (Scitech)
      in clinical settings when used according to the indications of the IFU.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Primary Patency Rate at 12 month follow-up</measure>
    <time_frame>12 months post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary Patency Rate at 1- and 6 month follow-up</measure>
    <time_frame>1 monthand 6 months post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Graft Occlusion Rate at pre-discharge, 1-, 6-, and 12-month follow-up</measure>
    <time_frame>1day, 1 month, 6 month and 12 month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ankle-Brachial Index at 1-, 6- and 12-month follow-up compared with baseline ABI</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amputation rate at 1-, 6- and 12-month follow-up, defined as any amputation above the knee</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance success rate at baseline</measure>
    <time_frame>during procedure</time_frame>
    <description>defined as a composite of (a) successful in sealing acute perforation or rupture; (b) successful in treating aneurysm and fistulae ; (c) restoration of blood flow</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>in-stent restenosis rate at 1-, 6- and 12-month post-op</measure>
    <time_frame>1-, 6-, 12-month post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom from Target Lesion Revascularization at 1-, 6- and 12-month post-op</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
    <description>defined as freedom from a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the treated lesion edge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE's) until 12-month post-op</measure>
    <time_frame>within 12-months post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>during procedure</time_frame>
    <description>defined as the ability to achieve final residual angiographic stenosis no greater than 30%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success at follow-up</measure>
    <time_frame>1-, 6- and 12-month post-op</time_frame>
    <description>defined as an improvement of Rutheford Classification at 1-, 6- and 12-month follow-up of one class or more as compared to the pre-procedure Rutherford classification</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Peripheral Arterial Disease</condition>
  <condition>Iliac Artery Stenosis</condition>
  <condition>Common Femoral Artery Stenosis</condition>
  <arm_group>
    <arm_group_label>Solaris Vascular Stent Graft</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Solaris Vascular Stent Graft</intervention_name>
    <description>Solaris Vascular Stent Graft for treatment of Iliac Lesions</description>
    <arm_group_label>Solaris Vascular Stent Graft</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        see inclusion criteria
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Corresponding to the IFU indications/contra-indications and according to the current
             medical guidelines for minimally invasive peripheral interventions.

          -  Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable
             for stenting (on indication for primary stenting, based on the discretion of the
             investigator)

          -  Patient presenting a score from 2 to 5 following Rutherford classification

          -  Patient is willing to comply with specified follow-up evaluations at the specified
             times for the duration of the study

          -  Patient is &gt;18 years old

          -  Patient (or their legal representative) understands the nature of the procedure and
             provides written informed consent, prior to enrolment in the study

          -  The target lesion is either a modified TASC-II class A, B, C or D lesion with one of
             the listed specifications:

               -  Type A lesions

                    -  Unilateral or bilateral stenoses of the Common Iliac Artery

                    -  Unilateral or bilateral single short (â‰¤3 cm) stenosis of the External Iliac
                       Artery

               -  Type B lesions

                    -  Unilateral Common Iliac Artery occlusion

                    -  Single or multiple stenosis totaling 3-10 cm involving the External Iliac
                       Artery not extending into the Common Femoral Artery

                    -  Unilateral External Iliac Artery occlusion not involving the origins of
                       Internal Iliac Artery or Common Iliac Artery

               -  Type C lesions

                    -  Bilateral Common Iliac Artery occlusions

                    -  Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the
                       Common Femoral Artery

                    -  Unilateral External Iliac Artery stenosis extending into the Common Femoral
                       Artery

                    -  Unilateral External Iliac Artery occlusion that involves the origins of the
                       Internal Iliac and/or Common Femoral Artery

                    -  Heavily calcified unilateral External Iliac Artery occlusion with or without
                       involvement of origins of the Internal Iliac and/or Common Femoral Artery

               -  Type D lesions

                    -  Unilateral occlusions of both Common Iliac and External Iliac Artery

                    -  Diffuse disease involving the aorta and both iliac arteries requiring
                       treatment

                    -  Bilateral occlusions of External Iliac Artery

          -  The target lesion has angiographic evidence of stenosis or restenosis &gt; 50% or
             occlusion which can be passed with standard guidewire manipulation

          -  There is angiographic evidence of a patent Common and Deep Femoral Artery

        Exclusion Criteria:

          -  PTA is technically not possible (not feasible to access the lesion or a defect with
             the guidewire or balloon catheter)

          -  Presence of an aneurysm immediately adjacent to the site of stent implantation

          -  Stenosis distal to the site of stent implantation

          -  Lesions in or adjacent to essential collaterals(s)

          -  Lesions in locations subject to external compression

          -  Heavily calcified lesions resistant to PTA

          -  Patients with diffuse distal disease resulting in poor stent outflow

          -  Patients with a history of coagulation disorders

          -  Patients with aspirin allergy or bleeding complications and patients unable or
             unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to
             anticoagulant/antiplatelet therapy

          -  Fresh thrombus formation

          -  Patients with known hypersensitivity to the stent material (L605) and/or PTFE

          -  The target lesion is either a modified TASC-II class B or D lesion with aortic or
             common femoral lesion involvement:

               -  Type B lesions

                  â€¢ Short (â‰¤3 cm) stenosis of infrarenal aorta

               -  Type D lesions

                    -  Infra-renal aortoiliac occlusion

                    -  Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring
                       treatment and not amenable to endograft placement or other lesions requiring
                       open aortic or iliac surgery

                    -  Diffuse multiple stenoses involving the unilateral Common Iliac, External
                       Iliac and Common Femoral Artery

          -  Previously implanted stent(s) at the same lesion site

          -  Reference segment diameter is not suitable for the available stent design

          -  Untreatable lesion located at the distal outflow arteries

          -  Use of alternative therapy (e.g. atherectomy, cutting balloon, laser, radiation
             therapy) as part of the index procedure

          -  Patients refusing treatment

          -  Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are
             contraindicated

          -  Patients who exhibit persistent acute intraluminal thrombus of the proposed lesion
             site

          -  Perforation at the angioplasty site evidenced by extravasation of contrast medium

          -  Patients with a history of prior life-threatening contrast medium reaction

          -  Patients with uncorrected bleeding disorders

          -  Female patient with child bearing potential not taking adequate contraceptives or
             currently breastfeeding

          -  Life expectancy of less than twelve months

          -  Any planned surgical intervention/procedure within 30 days of the study procedure

          -  Any patient considered to be hemodynamically unstable at onset of procedure

          -  Patient is currently participating in another investigational drug or device study
             that has not completed the entire follow up period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Torsello, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>FCRE (Foundation for Cardiovascular Research and Education)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeroen Wauters</last_name>
    <phone>+3252252822</phone>
    <email>jeroen.wauters@fcre.eu</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 5, 2020</study_first_submitted>
  <study_first_submitted_qc>March 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>FCRE (Foundation for Cardiovascular Research and Education)</investigator_affiliation>
    <investigator_full_name>Prof. Giovanni Torsello</investigator_full_name>
    <investigator_title>Study Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

